ArticleBMC cancer2025
Predictors of quality of life in multiple myeloma patients: a multi-centered cross-sectional study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical characteristics, laboratory measures, and quality of life as predictors of medication adherence in multiple myeloma.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple myeloma (MM) substantially impairs health-related quality of life (QoL). Evidence from low- and middle-income countries is limited, and identifying reliable predictors of QoL is essential to guide supportive care strategies.
methodsWe conducted a multicenter cross-sectional study of 202 MM patients from six hospitals in the West Bank, Palestine (2018-2025). Patients completed the validated Arabic EORTC QLQ-MY20 questionnaire. Clinical, demographic, and therapeutic variables were collected, and predictors of QoL subscales were analyzed using non-parametric tests and multivariable linear regression with LASSO variable selection.
resultsIn the Side Effects of Treatment subscale, abdominal pain (β = 6.75; 95% CI: 1.92-11.59; p = 0.006), chest pain (β = 9.63; 95% CI: 4.25-15.01; p < 0.001), and swelling (β = 8.15; 95% CI: 2.90-13.40; p = 0.002) were strong independent predictors, while autoimmune disease and peptic ulcer showed borderline associations. For the Body Image subscale, gout (β = - 22.06; 95% CI: - 38.95 to - 5.18; p = 0.010) and peptic ulcer (β = - 25.82; 95% CI: - 47.18 to - 4.46; p = 0.018) significantly worsened patient perceptions, with serum calcium showing a borderline effect (p = 0.052). In the Future Perspective subscale, chest pain demonstrated a borderline negative association (β = - 8.15; 95% CI: - 16.72 to 0.42; p = 0.062), while other predictors showed no significant effects. LASSO models confirmed stable predictor sets with low multicollinearity, explaining 25.9% (SE), 10.5% (Body Image), and 2.4% (Future Perspective) of variance, respectively.
conclusionsSpecific symptoms (abdominal pain, chest pain, swelling) and comorbidities (gout, peptic ulcer disease) emerged as important determinants of QoL in MM patients. Cardiopulmonary complaints also suggested a psychological burden on future outlook. These findings highlight the need for integrated symptom management and comorbidity-focused supportive care, particularly in resource-limited healthcare systems such as Palestine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.